Duration of Ticagrelor (Brilinta) for Recurrent Stroke Prevention
For patients with acute ischemic stroke or high-risk TIA, ticagrelor plus aspirin should be given for 30 days only, not longer. 1
Evidence-Based Dosing Regimen
The FDA-approved and guideline-supported protocol is 1:
- Loading dose: Ticagrelor 180 mg plus aspirin 300-325 mg on day 1
- Maintenance: Ticagrelor 90 mg twice daily plus aspirin 75-100 mg daily
- Duration: 30 days total
- First maintenance dose timing: 6-12 hours after loading dose 1
Why 30 Days is the Correct Duration
Short-Term DAPT is Superior to Long-Term
The evidence strongly distinguishes between short-term versus long-term dual antiplatelet therapy (DAPT) 2:
Short-term DAPT (≤90 days): Reduces recurrent ischemic stroke by 32% (pooled RR 0.68,95% CI 0.55-0.83) without significantly increasing major bleeding (pooled RR 1.88,95% CI 0.93-3.83) 2
Long-term DAPT (>90 days): Shows NO significant reduction in recurrent stroke (pooled RR 0.89,95% CI 0.79-1.02) but DOES significantly increase major bleeding risk (pooled RR 2.42,95% CI 1.37-4.30) 2
The THALES Trial Established 30-Day Treatment
The pivotal THALES trial that led to FDA approval used exactly 30 days of treatment 1, 3:
- Efficacy: Reduced stroke or death from 6.5% to 5.4% (17% relative risk reduction, NNT=92) 2, 3
- Safety concern: Increased severe bleeding from 0.1% to 0.5% (NNH=263) 2, 3
- Timing of benefit: Most benefit accrued in the first 10 days and was sustained at 30 days 1, 4
The Benefit-Risk Balance Favors 30 Days
Analysis of the time-course shows 4:
- Week 1: Absolute risk reduction of major ischemic events was 1.15% (95% CI 0.36-1.94%), with net clinical benefit favoring ticagrelor-aspirin 4
- Throughout 30 days: The ischemic benefit consistently outweighed hemorrhagic risk, with absolute risk increase in major hemorrhage remaining constant at approximately 0.3% 4
- Beyond 30 days: No evidence supports continuation, and bleeding risk accumulates 2
Critical Eligibility Criteria
Only use this regimen in patients meeting these criteria 1:
- Stroke severity: NIHSS score ≤5 (mild-to-moderate) 1, 3
- Timing: Within 24 hours of symptom onset 1, 3
- Stroke type: Non-cardioembolic 1, 3
- Exclusions:
After 30 Days: Transition to Monotherapy
At day 31, discontinue ticagrelor and continue aspirin monotherapy alone 2. The 2021 AHA/ASA guidelines clearly state that long-term DAPT beyond the initial period is not beneficial and increases bleeding risk 2.
Special Consideration: Atherosclerotic Stenosis
Patients with ipsilateral atherosclerotic stenosis ≥30% derive greater absolute benefit 5:
- With stenosis: 8.1% vs 10.9% event rate (NNT=34) 5
- Without stenosis: 4.8% vs 5.4% event rate 5
- Duration remains 30 days even in this higher-risk subgroup 5
Common Pitfall to Avoid
Do not extend ticagrelor beyond 30 days thinking "more is better" - this is the most critical error. The evidence unequivocally shows that prolonged DAPT increases bleeding without additional ischemic benefit 2. The FDA label specifically states 30 days for acute ischemic stroke/TIA 1, and guideline meta-analyses confirm harm with longer duration 2.